Join

or

Existing user? Login

New medicine

New treatment for chronic obstructive pulmonary disease

Olodaterol, a once-daily long acting β2-agonist inhaler, has been launched in the UK for chronic obstructive pulmonary disease.

Launch of new treatment for chronic obstructive pulmonary disease (COPD)

Source: istockphoto.com

Sufferers of chronic obstructive pulmonary disease have a new drug to aid treatment

Olodaterol, a once-daily long acting beta2 agonist (LABA) inhaler, has been launched in the UK as an additional treatment option for chronic obstructive pulmonary disease (COPD).

The treatment is indicated as a maintenance bronchodilator treatment in patients with COPD. Improvement in lung function is comparable to formoterol and tiotropium, according to the summary of product characteristics.

“For people with mild or moderate COPD who remain breathless despite short-acting bronchodilators and who are not having frequent exacerbations, the LABAs offer an [equally] as effective alternative to the long-acting muscarinic antagonists such as tiotropium,” says Anna Murphy, consultant respiratory pharmacist at University Hospitals of Leicester NHS Trust.

A number of LABAs used for COPD already exist on the market, including formoterol, indacterol and vilanterol.

It is essential to confirm a diagnosis of COPD prior to starting LABA treatment without an inhaled corticosteroid because, for asthmatic patients, this regimen carries an increased risk of death, she added.

The most common adverse events associated with olodaterol include nasopharyngitis, dizziness, hypertension, rash and arthralgia.

Olodaterol is being marketed by Boehringer Ingelheim as Striverdi Respimat. The company is also seeking marketing approval for a once-daily fixed-dose combination inhaler of olodaterol tiotropium as a maintenance treatment for patients with COPD.

 Factfile: Product details
 Action: long acting betaagonist
 Dose: 5mg per day taken as two puffs via an inhaler once daily
 Legal category: Prescription only medicine
 NHS list price: one inhaler and 60 puff cartridge (30 doses) £26.35

Citation: Electronicjuice DOI: 10.1211/PJ.2014.20065976

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00
  • Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00
  • Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00
  • Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

www.start-sport.com.ua

www.start-sport.com.ua/boevye-iskusstva/boks/bokserskie-perchatki

adulttorrent.org/search/ginger-banks